Video

Dr. Paty on Patients With Rectal Cancer Ineligible for "Watch and Wait"

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach with their surgeons.

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses patients with rectal cancer who are ineligible for a "watch and wait" approach.

Important factors to consider are tumor characteristics and the appearance of the rectal wall in the lymph nodes, Paty says. Tumors must be in a complete state of regression, which can be determined via cross-sectional imaging.

Tumors that are more difficult to eradicate are bulkier and larger in size are usually not fit for a "watch and wait" approach. Intermediate- and smaller-size tumors will likely have a higher cure rate via non-operative management; because they are smaller in size, it is easier to assess their response to treatment.

Patients with a lot of disease in the mesentery are also not appropriate candidates for "watch and wait," Paty says.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Tracy George, MD
Elias Jabbour, MD
Neil Iyengar, MD, and Chandler Park, MD, FACP
Bently P. Doonan, MD
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center
Aditya Bardia, MD, MPH, FASCO, professor, Department of Medicine, Division of Hematology/Oncology, director, Translational Research Integration, UCLA Health Jonsson Comprehensive Cancer Center
John M. Burke, MD